Skip to main content
. 2021 Feb 5;36(3):470–482. doi: 10.1002/jca.21881

TABLE 1.

Comparison of background characteristics and comorbidities between convalescent plasma and control

Study characteristics Convalescent plasma Control Comparison
Variable No. Studies Events (n/N) Prop (95% CI) Events (n/N) Prop (95% CI) OR (95% CI) P‐value I 2 (95% CI) P‐value (Q)
Male Sex 13 1484/2196 0.647 (0.562; 0.723) 1760/2615 0.679 (0.591; 0.755) 0.97 (0.85; 1.10) .633 0.0% (0.0; 58.9%) .392
IVIG Use 3 19/287 0.241 (0.150; 0.364) 25/293 0.298 (0.183; 0.445) 1.30 (0.56; 3.03) .539 0.0% (0.0; 79.0%) .609
Steroid Use 10 806/1164 0.659 (0.629; 0.688) 1027/1632 0.609 (0.582; 0.635) 1.04 (0.87; 1.23) .849 59.0 (14.4; 80.4%) .012
Oxygen Use 10 750/929 0.891 (0.861; 0.914) 1048/1271 0.825 (0.795; 0.851) 1.73 (1.24; 2.42) .001 80.8% (55.1; 91.8%) <.001
Antiviral Use 10 1376/1682 0.675 (0.618; 0.728) 1510/1761 0.691 (0.645; 0.733) 0.83 (0.58; 1.17) .278 0.0% (0.0; 16.6%) .911
Diabetes 13 752/2207 0.349 (0.329; 0.370) 904/2633 0.348 (0.330; 0.367) 1.04 (0.92; 1.18) .538 0.0% (0.0; 41.1%) .716
HTN 12 1028/2168 0.480 (0.459; 0.501) 1203/2477 0.489 (0.469; 0.509) 0.95 (0.84; 1.07) .422 0.0% (0.0; 57.3%) .465
COPD 7 93/990 0.107 (0.088; 0.129) 136/1344 0.120 (0.102; 0.140) 1.02 (0.76; 1.37) .901 17.1% (0.0; 61.0%) .300
CKD 9 130/1897 0.076 (0.064; 0.089) 202/2142 0.101 (0.088; 0.115) 0.81 (0.64; 1.02) .072 14.9% (0.0; 57.0%) .309
CVD 9 349/1878 0.223 (0.203; 0.245) 438/2130 0.238 (0.219; 0.259) 0.90 (0.76; 1.06) .200 0.0% (0.0; 18.3%) .903
Cerebrovascular disease 3 17/351 0.058 (0.003; 0.544) 20/467 0.029 (0.001; 0.499) 1.30 (0.63; 2.68) .477 0.0% (0.0; 87.9%) .425

Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HTN, hypertension; OR, odds ratio.